Hakutulokset - Chiranjeevi Sandi

  • Näytetään 1 - 10 yhteensä 10 tuloksesta
Tarkenna hakua
  1. 1
    Cellular, molecular and functional characterisation of YAC transgenic mouse models of Friedreich ataxia.

    Cellular, molecular and functional characterisation of YAC transgenic mouse models of Friedreich ataxia. Tekijä Sara Anjomani Virmouni, Chiranjeevi Sandi, Sahar Al-Mahdawi, Mark A Pook

    Julkaistu 2014-01-01
    Hae kokoteksti
    Artikkeli
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    Friedreich ataxia patient tissues exhibit increased 5-hydroxymethylcytosine modification and decreased CTCF binding at the FXN locus.

    Friedreich ataxia patient tissues exhibit increased 5-hydroxymethylcytosine modification and decreased CTCF binding at the FXN locus. Tekijä Sahar Al-Mahdawi, Chiranjeevi Sandi, Ricardo Mouro Pinto, Mark A Pook

    Julkaistu 2013-01-01
    Hae kokoteksti
    Artikkeli
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    MutLα heterodimers modify the molecular phenotype of Friedreich ataxia.

    MutLα heterodimers modify the molecular phenotype of Friedreich ataxia. Tekijä Vahid Ezzatizadeh, Chiranjeevi Sandi, Madhavi Sandi, Sara Anjomani-Virmouni, Sahar Al-Mahdawi, Mark A Pook

    Julkaistu 2014-01-01
    Hae kokoteksti
    Artikkeli
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    Generation and characterisation of Friedreich ataxia YG8R mouse fibroblast and neural stem cell models.

    Generation and characterisation of Friedreich ataxia YG8R mouse fibroblast and neural stem cell models. Tekijä Chiranjeevi Sandi, Madhavi Sandi, Harvinder Jassal, Vahid Ezzatizadeh, Sara Anjomani-Virmouni, Sahar Al-Mahdawi, Mark A Pook

    Julkaistu 2014-01-01
    Hae kokoteksti
    Artikkeli
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    A novel GAA-repeat-expansion-based mouse model of Friedreich’s ataxia

    A novel GAA-repeat-expansion-based mouse model of Friedreich’s ataxia Tekijä Sara Anjomani Virmouni, Vahid Ezzatizadeh, Chiranjeevi Sandi, Madhavi Sandi, Sahar Al-Mahdawi, Yogesh Chutake, Mark A. Pook

    Julkaistu 2015-03-01
    Hae kokoteksti
    Artikkeli
    Lisää suosikkeihin
    Tallennettuna:
  6. 6
    Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia.

    Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia. Tekijä Lingli Li, Lucille Voullaire, Chiranjeevi Sandi, Mark A Pook, Panos A Ioannou, Martin B Delatycki, Joseph P Sarsero

    Julkaistu 2013-01-01
    Hae kokoteksti
    Artikkeli
    Lisää suosikkeihin
    Tallennettuna:
  7. 7
    The mismatch repair system protects against intergenerational GAA repeat instability in a Friedreich ataxia mouse model

    The mismatch repair system protects against intergenerational GAA repeat instability in a Friedreich ataxia mouse model Tekijä Vahid Ezzatizadeh, Ricardo Mouro Pinto, Chiranjeevi Sandi, Madhavi Sandi, Sahar Al-Mahdawi, Hein te Riele, Mark A. Pook

    Julkaistu 2012-04-01
    Hae kokoteksti
    Artikkeli
    Lisää suosikkeihin
    Tallennettuna:
  8. 8
    Pms2 suppresses large expansions of the (GAA·TTC)n sequence in neuronal tissues.

    Pms2 suppresses large expansions of the (GAA·TTC)n sequence in neuronal tissues. Tekijä Rebecka L Bourn, Irene De Biase, Ricardo Mouro Pinto, Chiranjeevi Sandi, Sahar Al-Mahdawi, Mark A Pook, Sanjay I Bidichandani

    Julkaistu 2012-01-01
    Hae kokoteksti
    Artikkeli
    Lisää suosikkeihin
    Tallennettuna:
  9. 9
    Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model

    Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model Tekijä Chiranjeevi Sandi, Ricardo Mouro Pinto, Sahar Al-Mahdawi, Vahid Ezzatizadeh, Glenn Barnes, Steve Jones, James R. Rusche, Joel M. Gottesfeld, Mark A. Pook

    Julkaistu 2011-06-01
    Hae kokoteksti
    Artikkeli
    Lisää suosikkeihin
    Tallennettuna:
  10. 10
    Identification of potential therapeutic targets in prostate cancer through a cross‐species approach

    Identification of potential therapeutic targets in prostate cancer through a cross‐species approach Tekijä Sarah Jurmeister, Antonio Ramos‐Montoya, Chiranjeevi Sandi, Nelma Pértega‐Gomes, Karan Wadhwa, Alastair D Lamb, Mark J Dunning, Jan Attig, Jason S Carroll, Lee GD Fryer, Sérgio L Felisbino, David E Neal

    Julkaistu 2018-03-01
    Hae kokoteksti
    Artikkeli
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: